SynthesisRheumatology international2025
Prevalence and risk factors of renal involvement in seronegative spondyloarthropathies: a systematic review.
Synthesis in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Seronegative spondyloarthritis (SpA) comprises a heterogeneous group of rheumatic diseases characterized by axial and peripheral joint involvement, as well as extra-articular manifestations, including uveitis, psoriasis, and inflammatory bowel disease. Although renal involvement in SpA is less understood, evidence suggests it may result from disease activity, chronic inflammation, or therapeutic agents. The underlying pathophysiology remains unclear. This systematic review evaluates the prevalence and risk factors associated with renal abnormalities in SpA. A systematic literature search was conducted following the latest Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from 26 studies published between 1980 and 2025 were synthesized. Extracted variables included study author, year and location of publication, sample size, renal assessment parameters, prevalence of renal involvement, presence of control groups, and statistical significance of findings. Renal involvement in SpA, assessed through hematuria, proteinuria, estimated glomerular filtration rate, and International Classification of Diseases codes, showed considerable variability, with prevalence ranging from 0.2 to 77.5%. Nephrolithiasis was also more common among SpA patients, with reported rates between 1.6% and 29.1%. Potential risk factors, including age, disease activity, comorbidities, and HLA-B27 status, were explored, though findings remained inconsistent. This review highlights significant methodological discrepancies among studies assessing renal involvement in SpA. Further research is needed to clarify the renal complications associated with SpA and establish reliable risk factors. PROSPERO Registration: CRD42024579791.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.